Purple Biotech .(US:PPBT)2026-03-19 01:11Financial Position - Total cash position was $9.5 million as of December 31, 2025, expected to provide runway into 2027[1] - Total assets decreased to $17.572 million as of December 31, 2025, from $37.038 million in 2024[21] - Cash and cash equivalents at the end of the year on December 31, 2025, were $8,717,000, an increase from $7,401,000 at the beginning of the year[24] Expenses - Research and Development Expenses for Q4 2025 were $1.8 million, an increase of $1.4 million compared to $0.5 million in Q4 2024[6] - General and Administrative Expenses for Q4 2025 were $1.1 million, an increase of $0.6 million compared to $0.6 million in Q4 2024[7] - Research and development expenses for the year ended December 31, 2025, were $3,731,000, a decrease of 51% from $7,620,000 in 2024[22] - The impairment loss for the year ended December 31, 2025, was $20,482,000, a significant increase from $202,000 in 2024[22] Losses - Operating Loss for the year ended December 31, 2025, was $27.5 million, an increase of $16.5 million compared to $11 million in 2024[15] - Net Loss for the year ended December 31, 2025, was $26.4 million, or $54.9 loss per basic ADS, compared to a net loss of $7.2 million in 2024[16] - The total comprehensive loss for the year ended December 31, 2025, was $26,492,000, up from $7,298,000 in 2024, indicating a significant increase of 263%[22] - The loss per share for the year ended December 31, 2025, was $0.027, compared to $0.022 in 2024, representing a 23% increase[22] Cash Flow - The net cash used in operating activities for the year ended December 31, 2025, was $5,656,000, an improvement from $14,367,000 in 2024[24] - The company reported a non-IFRS adjusted operating loss of $6,667,000 for the year ended December 31, 2025, compared to $10,221,000 in 2024, reflecting a 35% improvement[25] - The company raised $3,153,000 from the issuance of ADSs during the year ended December 31, 2025, down from $5,809,000 in 2024[24] - The finance income, net for the year ended December 31, 2025, was a loss of $966,000, compared to a loss of $3,726,000 in 2024, indicating an improvement[24] Research and Development - Achieved commercially viable yield for IM1240, positioning the program competitively for future development[14] - Significant tumor regression demonstrated with IM1240 and IM1305, targeting different tumor antigens[5] - CAPTN-3 platform's lead candidate, IM1240, showed improved tolerability in toxicology studies at doses up to 300-fold higher than a non-capped comparator[5]